{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:54:00Z","timestamp":1772556840995,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.arcmed.2025.103290","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T01:54:37Z","timestamp":1756950877000},"page":"103290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factor VIII Pharmacokinetics in Mexican Patients with Hemophilia A"],"prefix":"10.1016","volume":"57","author":[{"given":"Jes\u00fas","family":"Hernandez-Juarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Espejo-Godinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julieta","family":"Espinoza-Islas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Manuel Dominguez","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-4651","authenticated-orcid":false,"given":"Jaime","family":"Garcia-Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berenice","family":"Fernandez-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-5790","authenticated-orcid":false,"given":"Abraham","family":"Majluf-Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2025.103290_bib0001","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/hematolrep15010014","article-title":"Haemophilia A: a review of clinical manifestations, treatment, mutations, and the development of inhibitors","volume":"15","author":"Sarmiento Doncel","year":"2023","journal-title":"Hematol Rep"},{"key":"10.1016\/j.arcmed.2025.103290_bib0002","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arcmed.2025.103290_bib0003","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2025.103290_bib0004","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arcmed.2025.103290_bib0005","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/ph15080911","article-title":"Immunogenicity of current and new therapies for hemophilia A","volume":"15","author":"Prezotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.arcmed.2025.103290_bib0006","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2516.1998.440409.x","article-title":"Prophylactic treatment in Sweden\u2013overtreatment or optimal model?","volume":"4","author":"Ljung","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.arcmed.2025.103290_bib0007","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3\u201374 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bj\u00f6rkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2025.103290_bib0008","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","article-title":"Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arcmed.2025.103290_bib0009","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003088-200140110-00003","article-title":"Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia","volume":"40","author":"Bj\u00f6rkman","year":"2001","journal-title":"Clin Pharmacokin"},{"key":"10.1016\/j.arcmed.2025.103290_bib0010","first-page":"1","article-title":"The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A","volume":"19","author":"McEneny-King","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.arcmed.2025.103290_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100852","article-title":"Optimising prophylaxis in haemophilia A: the ups and downs of treatment","volume":"50","author":"Berntorp","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.arcmed.2025.103290_bib0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2516.2008.01864.x","article-title":"The disappearing act of factor VIII","volume":"16","author":"Lenting","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.arcmed.2025.103290_bib0013","doi-asserted-by":"crossref","first-page":"19","DOI":"10.32607\/20758251-2013-5-2-19-39","article-title":"Blood clotting Factor VIII : from evolution to therapy","volume":"5","author":"Orlova","year":"2013","journal-title":"Acta Naturae"},{"key":"10.1016\/j.arcmed.2025.103290_bib0014","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2516.2011.02568.x","article-title":"Factor VIII inhibitors: a 50-year perspective","volume":"17","author":"Green","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.arcmed.2025.103290_bib0015","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2025.103290_bib0016","first-page":"19","article-title":"Economic impact of hemophilia type A and B in Mexico","volume":"152","author":"Carlos-Rivera","year":"2016","journal-title":"Gac Med Mex"},{"key":"10.1016\/j.arcmed.2025.103290_bib0017","first-page":"239","article-title":"Current understanding of inherited modifiers of FVIII pharmacokinetic variation","volume":"16","author":"Swystun","year":"2023","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.arcmed.2025.103290_bib0018","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/jth.14469","article-title":"Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: is there a difference?","volume":"17","author":"Carcao","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arcmed.2025.103290_bib0019","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/hae.12294","article-title":"Correlation between endogenous VWF: AG and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS","volume":"20","author":"Lalezari","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.arcmed.2025.103290_bib0020","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1111\/hae.14649","article-title":"Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics","volume":"28","author":"Nummi","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.arcmed.2025.103290_bib0021","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/hae.13561","article-title":"BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies","volume":"24","author":"Shah","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.arcmed.2025.103290_bib0022","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1111\/jth.15395","article-title":"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database","volume":"19","author":"Versloot","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arcmed.2025.103290_bib0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2516.9.s1.4.x","article-title":"Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective","volume":"9","author":"Bj\u00f6rkman","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.arcmed.2025.103290_bib0024","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2516.1997.00091.x","article-title":"Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A","volume":"3","author":"Carlsson","year":"1997","journal-title":"Haemophilia"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440925001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440925001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:49:26Z","timestamp":1772549366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440925001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0188440925001109"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103290","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor VIII Pharmacokinetics in Mexican Patients with Hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103290"}}